Beam’s medicine uses a technology known as base editing to activate a gene in stem cells collected from people with sickle ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement from ...

We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.

By Michael Erman and Bhanvi Satija (Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...

Enrollment has finished for the Phase 3 RISE UP study, which is testing the oral therapy mitapivat in people with sickle cell ...

Topline Data from 52-week Phase 3 Study Expected in Late 2025 –CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, ...

Sickle cell disease summit hosted by HHS highlights advancements and challenges. Learn about the summit and the experiences ...